Form 4: Fennec Pharmaceuticals CFO Robert Andrade Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, sold 13,975 common shares at $10.9975 per share on March 25, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, sold 13,975 common shares of the company on March 25, 2024.
- The sale was executed at a price of $10.9975 per share.
- Following the transaction, Andrade directly owns 105,746 common shares.
- The sale was conducted under a pre-arranged 10b5-1 trading plan adopted on August 16, 2023.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reporting a routine share sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Sales under a 10b5-1 plan are generally viewed as less informative since they are pre-scheduled and intended to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 08/16/2023 | Date of adoption of the 10b5-1 trading plan. |
| 03/25/2023 | Date of earliest transaction listed on the form. |
| 03/25/2024 | Date of the share sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.